Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Low-dose hypomethylating agents cooperate with ferroptosis inducers to enhance ferroptosis by regulating the DNA methylation-mediated MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway in acute myeloid leukemia

Fig. 1

GPX4 expression is higher in AML blasts than in normal controls (NCs). (A) The relative expressions of GPX4 were assessed in AML blasts and normal hematological stem and progenitor cells (HSPCs) as normal controls (NCs) from the BloodSpot database. (B) The relative expressions of GPX4 were determined in AML blasts with different chromosome karyotypes from the BloodSpot database. (C) The relative expressions of GPX4 were assessed in AML cells with t(11q23) arrangement and NCs based on the GSE13159 database. (D) The relative expressions of GPX4 were assessed in PB and BM cells from AML patients and NCs based on the GSE9476 database. (E) The relative expressions of GPX4 were assessed in healthy BM as NC and AML patients from database of Leukemia Mile study. (F) The relative expressions of GPX4 were assessed in different AML karyotype from Leukemia Mile study database. NK: normal karyotype. (G) The protein levels of GPX4 were measured in four NCs and four AML samples. (H) GPX4 enzyme activities were measured in four NCs and ten AML samples. (I) GPX4 enzyme activities were analyzed in three R/R-AML and seven non-R/R-AML cells. (J and K) The overall survival of AML patients with higher expression of GPX4 (above median) and lower expression of GPX4 (below median) was assessed in the GSE1729 (J) and TCGA databases (K). *P < 0.05; **P < 0.01; ***P < 0.001 versus NCs. N.S: not significant

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us